Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 with IMRT in Inoperable Recurrent Nasopharyngeal Carcinoma
NCT04895345Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in nasopharyngeal carcinoma (NPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2021; status: completed.
02
Drugs
benmelstobart
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04895345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895345.